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Differential associations of symptom dimensions with prognosis in myocardial infarction (MI) 
patients have been shown for depression, but no studies have focused on anxiety dimensions. 
The aim of this study was to assess the association between somatic and psychological 
symptoms of anxiety following acute MI with adverse prognosis and to assess the overlap 
between anxiety and depression dimensions. 
Methods 
Patients (n=418) were assessed on demographic and clinical variables. The Hamilton Anxiety 
and Depression Rating Scales were used to measure anxiety and depression 2 months post-MI. 
Mean follow-up period was 3.8 years and the endpoint consisted of all-cause mortality and 
recurrent MI.  
Results 
After adjustment for demographic and clinical variables, somatic anxiety was significantly 
associated with recurrent MI and mortality (HR: 1.32; 95% CI: 1.03-1.69; p=0.03), while a trend 
was shown for an association between psychological anxiety and outcome (HR: 1.29; 95% CI: 
0.99-1.67; p=0.06). The total anxiety score of the HARS was the strongest predictor of recurrent 
MI and mortality (HR: 1.38; 95% CI: 1.07-1.78; p=0.02). The HARS and the HDRS were highly 
correlated (r=0.86; p<0.01). Dimensions consisting of psychological distress (HR: 1.29; 95% CI: 
1.02-1.63; p=0.03) and cardiopulmonary/autonomic symptoms (HR: 1.36; 95% CI: 1.06-1.75; 
p=0.02) also predicted outcome in adjusted analyses.  
Conclusions 
Anxiety was associated with adverse prognosis in MI patients with significant associations for 
somatic anxiety and total anxiety. When combining anxiety and depression items, psychological 




research might better focus on dimensions of anxiety and depression simultaneously in MI 
patients.  
 







Anxiety and depression after acute myocardial infarction (MI) are associated with negative 
outcomes like worse quality of life, increased health care consumption, and higher rates of 
cardiac events and mortality [Lane et al. 2001; Strik et al. 2003; Barth et al. 2004; van Melle et 
al. 2004]. A meta-analysis on the relationship between anxiety and cardiac prognosis showed 
that post-MI anxiety was associated with a 36% increased risk of cardiac morbidity and mortality 
[Roest et al. 2010]. However, this meta-analysis did not adjust for measures of cardiac disease 
severity [Roest et al. 2010]. 
Recently, there has been wide interest in the potential differential associations of symptom 
dimensions of depression with cardiac prognosis in patients with coronary heart disease (CHD). 
It has been suggested that depression in patients with CHD consists of two different symptom 
clusters of depression, a cognitive/affective and a somatic cluster which partly differ in etiology, 
expression of symptoms, and association with prognosis [Ormel and de Jonge 2011]. The 
etiology of cognitive/affective depressive symptoms might be characterized by known risk 
factors of depression, including vulnerability factors and stressful life events [Ormel and de 
Jonge 2011]. This theory is supported by the finding that aspects of cognitive vulnerability, 
namely locus of control and explicit self-depressive associations, were more strongly related to 
changes in cognitive/affective as compared to somatic symptoms of depression in participants of 
the Netherlands study of depression and anxiety [Struijs et al. 2013]. Somatic depressive 
symptoms on the other hand might be a result of physiological mechanisms also related to 
cardiovascular disease, such as hypothalamus-pituitary-adrenal (HPA) axis dysregulation 
autonomic nervous system dysfunction, and increased inflammation [Ormel and de Jonge 2011; 
Poole et al. 2011]. A recent study found some support for the role of inflammatory markers, 




acute coronary syndrome (ACS), although the pattern of findings was inconsistent [Steptoe et al. 
2013].  
Several studies showed that somatic depressive symptoms were stronger predictors of 
cardiac events as compared to cognitive/affective depressive symptoms in different patient 
groups [De Jonge et al. 2006; Schiffer et al. 2009; Smolderen et al. 2009; Martens et al. 2010b; 
Hoen et al. 2010b; Roest et al. 2011].Yet, not all studies have shown the differential importance 
of somatic depressive symptoms [Barefoot et al. 2000; Frasure-Smith and Lespérance 2003]. In 
addition, in two studies in patients treated with coronary artery bypass graft surgery (CAGB) 
only cognitive/affective symptoms predicted cardiac mortality [Connerney et al. 2010] and 
cardiovascular events [Tully et al. 2011].  
The extent to which the association between somatic depressive symptoms and adverse 
cardiac outcomes can be attributed to somatic complaints related to cardiac disease severity has 
been the object of debate [De Jonge et al. 2006; Martens et al. 2010b; Roest et al. 2011]. 
Complaints from cardiovascular or medical diseases and somatic depressive symptoms can 
intertwine and symptoms can be mistakenly interpreted as depressive symptoms. Indeed, 
depression has been found to be significantly related to severity of left ventricular dysfunction in 
MI patients [van Melle et al. 2005], although other studies did not find associations between 
depression and measures of cardiac disease severity, including left ventricular ejection fraction 
(LVEF) [Kronish et al. 2009; Lett et al. 2008]. However, a relationship between somatic 
depressive symptoms and LVEF has been shown as well [De Jonge et al. 2006; Martens et al. 
2010b].  
To our knowledge, no studies assessed whether there are subtypes of anxiety in patients with 
CHD or studied the potential differential associations of symptom dimensions of anxiety with 
prognosis. Therefore, the objective of the present study was to assess the association of somatic 




recurrent MI and mortality at follow-up. We hypothesized that somatic, and not psychological, 
symptoms of anxiety would be related to LVEF. Secondly, we hypothesized that cardiac disease 
severity does not fully explain the association between somatic anxiety symptoms and prognosis 
and that after controlling for cardiac risk factors somatic anxiety symptoms would be more 
strongly related to adverse outcome as compared to psychological anxiety symptoms. In 
addition, because anxiety and depression are closely associated in psychiatric [Watson 2005] and 
MI patients [Denollet et al. 2006] we assessed the overlap between somatic and psychological 




Patient population and procedure 
Between May 2003 and May 2006 acute MI-patients (n=477) were recruited during 
hospitalization from four hospitals in The Netherlands (Catharina Hospital, Eindhoven; St. Anna 
Hospital, Geldrop; St. Elisabeth Hospital and Tweesteden Hospital, Tilburg). Details of this 
study have been described elsewhere [Martens et al. 2010b]. Previous publications on this study 
examined amongst others the association of (dimensions of) depression with prognosis [Denollet 
et al. 2010; Martens et al. 2010b] but did not assess the association of anxiety with adverse 
cardiac outcomes. Prior to this study we performed an update of the outcome variables and 
therefore this study reports on a longer follow-up period. Criteria for diagnosis of MI were: 
troponin I levels more than twice the upper limit, with typical ischemic symptoms (e.g. chest 
pain) lasting for more than ten minutes or electrocardiogram evidence of ST segment elevation 
or new pathological Q-waves. Exclusion criteria were: severe medical co-morbidities that 
increased the likelihood of early death (e.g. malignant cancer); significant cognitive impairment 




(e.g. schizophrenia); and no command of the Dutch language. Medical ethics committees of the 
participating hospitals approved the study protocol and written informed consent was obtained 
from all patients after complete description of the study.  
 
Demographic and clinical characteristics 
Demographic variables included age, gender, partner status, and classified education level. 
Clinical variables were obtained from the patients’ medical record and included cardiac history 
(previous MI, percutaneous coronary intervention [PCI], or CABG prior to index MI), LVEF, 
medical co-morbidity (history of diabetes, renal insufficiency, chronic obstructive pulmonary 
disease [COPD], and arthritis), multi-vessel disease, anterior location of index MI, participation 
in cardiac rehabilitation after index MI, smoking status (self-report), body mass index (BMI), 
hypercholesterolemia (total cholesterol > 6.50 mmol/l), hypertension (systolic blood pressure > 
140 mmHg and diastolic blood pressure > 90 mmHg) and systolic and diastolic blood pressure. 
The following medications prescribed at discharge were also noted: beta-blockers, angiotensin-
converting enzyme inhibitors, anti-coagulants, statins, aspirin, diuretics, and selective serotonin 
reuptake inhibitors (SSRIs).  
 
Anxiety and depressive symptoms 
Two months after hospital admission for acute MI, patients were assessed for anxiety and 
depressive symptoms using the Hamilton Anxiety Rating Scale (HARS) and the Hamilton 
Depression Rating Scale (HDRS). The HARS [Hamilton 1959; Maier et al. 1988] and HDRS 
[Hamilton, 1960] are psychiatric interviews which are widely used in research and in clinical 
trials assessing the efficacy of treatment for anxiety and depressive disorders.  
The HARS contains 14 items and each item is scored on a scale of 0 (not present) to 4 




18 indicates clinically significant levels of anxiety [Goodman et al. 2005]. The HARS contains 
two subscales measuring psychological (i.e. items 1-6, and 14) and somatic (i.e. items 7-13) 
anxiety [Maier et al. 1988]. We tested whether we could replicate this underlying structure in our 
sample since most studies using the HARS were performed in psychiatric samples. In addition, 
we tested whether the HARS is an appropriate measure to assess anxiety in our sample. 
Although the validity of the HDRS was shown for depression [Strik et al. 2001], the validity of 
the HARS has not been studied in MI patients yet. 
 
Anxiety and depressive disorder 
The presence of a current major depressive disorder (MDD) and anxiety disorder (consisting of 
panic disorder, social phobia, and generalized anxiety disorder) based on the diagnostic criteria 
listed in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) 
[American Psychiatric Association 1994] was assessed by means of the Composite International 
Diagnostic Interview (CIDI) [World Health Organization 1990]. Two months after hospital 
admission for acute MI the patients were assessed by one of the authors (EJM), trained in the 
administration of the CIDI by the official WHO CIDI training centre. 
 
Endpoint   
The composite endpoint combining all-cause mortality and/or recurrent MI was verified by 
medical records. The same criteria as for inclusion in the study were used to assess MI at follow-
up. The mean follow-up period was 3.8 years (SD=1.1 years), median=4.0 years (range 28-2003 
days), and follow-up data were complete for all patients (100%).  
 




Discrete and continuous variables were compared with the chi-square test and the independent-
samples t-test. Sensitivity and specificity of the HARS (cutoff score ≥ 18) to detect anxiety 
disorder was established. Principal component analysis (PCA) with oblimin rotation was used to 
assess whether we could replicate the underlying structure of the HARS. The number of 
components was identified by a scree plot. The Kaiser-Meyer-Olkin (KMO) test and Bartlett’s 
test of sphericity were applied as fit indices. The association between the identified components 
was investigated using the Pearson product-moment correlation coefficient. Linear regression 
analyses were used to evaluate the relationship between factor scores for the specific components 
using the regression method [Distefano et al. 2009] and LVEF. To investigate the impact of 
anxiety symptom components on mortality and recurrent MI at follow-up, first univariate Cox 
proportional hazard regression analyses were performed. In subsequent multivariate analyses we 
adjusted for potential predictors of mortality, namely age, gender, cardiac history, and LVEF. In 
addition, we tested whether other potential characteristics of cardiac disease severity that 
significantly differed between the event-free and the adverse outcome group were independent 
predictors of recurrent MI and mortality and subsequently adjusted for these variables in 
sensitivity analyses. The original HARS total score was transformed to z-scores to compare the 
association of anxiety symptom dimensions with adverse outcome with the association of the 
HARS total score with outcome.  
In addition, a PCA was performed for the HARS and HDRS items combined to assess the 
overlap between symptom dimensions of anxiety and depression. A similar procedure as 
described above was followed to assess the associations between the identified components and 
mortality and recurrent MI.  
Hazard ratios (HR) with 95% confidence intervals (CI) are reported. For all analyses, 






Of the original 477 patients, 59 did not have a HARS assessment and 7 patients were missing 
one or two answers to HARS questions. The missing values were replaced by individual average 
item-scores, leaving 418 (88%) patients to be included in the final analyses. Patients who did not 
have a HARS assessment were more likely to be female (p<0.01), but there were no differences 
concerning age (p=0.11) and measures of cardiac disease severity including LVEF (p=0.42), and 
cardiac history (p=0.15).  
The demographic and clinical characteristics of the current sample are shown in Table 1. 
Fifty (12%) patients died or had a recurrent MI during the follow-up period of which 24 events 
were attributable to recurrent MI and 26 to all-cause mortality.  
 
Prevalence of anxiety symptoms  
Forty (9.6%) patients had a HARS score of 18 or higher. The prevalence of individual symptoms 
of the HARS indicating moderate severity (score 2 or higher) was highest for insomnia (32.5%), 
respiratory symptoms (23.0%), somatic symptoms (muscular) (21.5%), and autonomic 
symptoms (20.6%). Prevalence of other somatic symptoms was below 20%. For the 
psychological symptoms the prevalence was highest for anxious mood (19.9%), cognitive 
changes (19.6%), and tension (17.2%).  Prevalence of other psychological symptoms was below 
15%. 
 
Sensitivity and specificity of the HARS 
Sixteen (3.9%) patients met criteria for diagnosis of a current anxiety disorder as measured with 
the CIDI. Mean HARS score for patients with an anxiety disorder was 21.8 (SD=9.1), compared 




sensitivity (69%) and specificity (93%) of the HARS were adequate for the predetermined cutoff 
of 18.  
 
Component structure of the HARS 
The KMO test (0.85) and Bartlett’s test of sphericity (p < 0.01) indicated that PCA was adequate 
for these data. Although 3 components had eigenvalues >1 the scree plot indicated a 2 
component solution and therefore we determined the optimal number of factors to be 2 (Table 2). 
The total explained variance was 42%. There was a moderately positive correlation between the 
two components (r=0.40, p<0.01). The two components that were constructed from the PCA 
reflected somatic and psychological symptoms of anxiety. However, contrary to earlier research 
[Hamilton 1959], insomnia loaded on the somatic component and loadings for genitourinary 
symptoms were weak for both components. Factor loadings were negative for the psychological 
component. Therefore, regression factor scores were multiplied by -1 to ensure that high 
regression factor scores reflected high psychological anxiety.  
 
Anxiety symptoms and LVEF 
Somatic ( = -0.05, t = -0.95, p = 0.34) and psychological anxiety symptoms ( = 0.04, t = 0.84, 
p = 0.40) were both unrelated to LVEF as a marker of disease severity.  
 
Demographic and clinical predictors of recurrent MI and mortality 
The demographic and clinical characteristics of patients stratified by outcome are presented in 
table 1. Patients who died or experienced a recurrent MI were older (p<0.01), more likely to have 
a history of MI, PCI, or CABG prior to the index MI (p<0.01) and to have a lower mean LVEF 
(p<0.01) than patients free of events. Further, patients with an adverse outcome during follow-up 
were more likely to have comorbid diseases (p=0.01) and less likely to have 




SSRIs (p=0.02) and less likely to be treated with statins (p<0.01) compared with event-free 
patients. Patients with an adverse outcome were also less likely to have had invasive treatment 
(p=0.03) and cardiac rehabilitation (p=0.04) and more likely to have a diagnosis of current MDD 
(p=0.04) and anxiety disorder (p=0.02) than patients free of events. When entering age, cardiac 
history, LVEF, comorbidity, invasive treatment, cardiac rehabilitation, hypercholesterolemia and 
use of diuretics and statins into a multivariate analysis, age (p=0.04), cardiac history (p<0.01) 
and the use of statins (p=0.02) remained independently related to recurrent MI and mortality 
while there was a trend for LVEF to predict adverse outcome (p=0.06). 
 
Anxiety dimensions and recurrent MI and mortality 
In univariate analyses, the somatic anxiety dimension (HR: 1.32; 95% CI: 1.05-1.64; p=0.02) 
was associated with recurrent MI and mortality, but the psychological anxiety dimension (HR: 
1.14; 95% CI: 0.89-1.47; p=0.31) was not (Table 3, models 1a and 1b).  
When controlling for age, gender, cardiac history and LVEF, the somatic anxiety 
dimension (HR: 1.32; 95% CI: 1.03-1.69; p=0.03) significantly predicted recurrent MI and 
mortality (Table 3, model 2a) and the psychological anxiety dimension (HR: 1.29; 0.99-1.67; 
p=0.06) showed a trend to predict adverse outcome (Table 3, model 2b). Because patients who 
had an event were less likely to be treated with statins and the use of statins was an independent 
predictor of adverse outcome, we adjusted for this variable in a sensitivity analysis. However, 
further adjustment for use of statins did not change the effect (somatic anxiety= HR: 1.33; 1.04-
1.70; p=0.03; psychological anxiety= HR: 1.27; 95% CI: 0.98-1.65; p=0.07).  
When including both anxiety dimensions in the same model, neither was significantly 
associated with the endpoint after adjustment for covariates (somatic anxiety= HR: 1.25; 95% 
CI: 0.96-1.63; p=0.10; psychological anxiety= HR: 1.19; 95% CI: 0.90-1.57; p=0.22). 
 




The total anxiety score of the HARS was a significant predictor of recurrent MI and mortality in 
both unadjusted (HR: 1.28; 95% CI: 1.02-1.61, p=0.04) and adjusted (HR: 1.38; 95% CI: 1.07-
1.78; p=0.01) analyses. Survival curves for patients with clinically significant symptoms of 
anxiety (HARS score ≥ 18) versus other patients are presented in figure 1. There was a trend for 
patients with clinically significant anxiety to be at an increased risk of adverse outcome in 
unadjusted (HR: 1.93; 95% CI: 0.91-4.11; p=0.09) analyses and after adjustment for age, sex, 
cardiac history and LVEF (HR: 2.04; 95% CI: 0.94-4.39; p=0.07).   
 
Overlap of anxiety and depressive symptoms and prognosis  
The HARS and the HDRS were highly correlated (r=0.86; p<0.01). When combining the HARS 
and HDRS in a PCA the scree plot indicated a 4 component solution. When retaining 4 
components the explained variance was 46% and correlations between the 4 components ranged 
from r=0.16 to r=0.30; p<0.01. The 4 component solution represented the following dimensions: 
1. psychological distress, 2. sleeping problems, 3. cardiopulmonary/autonomic symptoms, 4. 
functional disability/fatigue. Psychological distress (HR: 1.29; 95% CI: 1.02-1.63; p=0.03) 
predicted recurrent MI and mortality after adjustment for age, gender, cardiac history and LVEF. 
Also cardiopulmonary/autonomic symptoms (cardiovascular, respiratory, gastrointestinal, 
autonomic, muscular and sensory symptoms from HARS, gastrointestinal and somatic anxiety 
symptoms from HDRS), independently predicted adverse outcome (HR: 1.36; 95% CI: 1.06-
1.75; p=0.02). Sleep problems (HR: 1.03; 95% CI: 0.79-1.35; p=0.82) and functional 







This study is the first to assess the association between anxiety dimensions and cardiac prognosis 
in a sample of patients who had experienced an acute MI. We replicated the existence of a 
somatic and psychological anxiety symptom dimension as measured with the HARS in this 
group of MI patients but, contrary to previous research in psychiatric samples [Hamilton 1959; 
Maier et al. 1988], insomnia loaded highly on the somatic component instead of the 
psychological component. This is consistent with studies focusing on dimensions of depression 
in which insomnia was also counted as a somatic symptom [De Jonge et al. 2006; Martens et al. 
2010b; Roest et al. 2011]. Somatic or psychological symptoms of anxiety were not associated 
with LVEF at baseline. After adjustment for demographic and clinical variables, including 
measures of disease severity, the somatic anxiety symptom dimension predicted recurrent MI 
and mortality at follow-up while a trend was shown for an association between psychological 
anxiety and outcome. In addition, the total anxiety score of the HARS was the strongest predictor 
of recurrent MI and mortality. There was a large overlap between psychological symptoms of 
anxiety and depression and a dimension of psychological distress was independently related to 
adverse prognosis. When looking at the somatic symptoms of anxiety and depression, three 
dimensions were found of which only one (cardiopulmonary/autonomic symptoms) predicted 
recurrent MI and mortality.   
To our knowledge one previous study assessed the association between symptom 
dimensions of anxiety and development of CHD. In this study in adults initially free from 
cardiovascular disease, anxiety, and particularly somatic anxiety, was related to an increased risk 
of CHD in women but not in men [Nabi et al. 2010]. When comparing our results with previous 
findings on the association of depression dimensions with cardiac disease severity and prognosis 
in patients with heart disease, our findings are somewhat different.  In studies representing 
patients with different stages of cardiac disease, including women with suspected myocardial 




2009; Martens et al. 2010b; Roest et al. 2011], and chronic heart failure patients [Schiffer et al. 
2009], an adverse association of somatic depressive symptoms, but not of cognitive/affective 
depressive symptoms, was found with medical prognosis. On the other hand, studies in CABG 
patients showed an adverse impact of cognitive/affective depressive symptoms and not of 
somatic depressive symptoms on cardiac morbidity and mortality [Connerney et al. 2010; Tully 
et al. 2011]. In addition, some studies highlighted specific cognitive/affective symptoms, like 
anhedonia [Davidson et al. 2010] and hopelessness [Denollet et al. 2013] as important predictors 
of cardiac outcomes, and these symptoms might be particularly important in relatively younger 
patients [Denollet et al. 2013].  
More research is needed to understand why studies on the relationship between 
dimensions of distress and cardiac prognosis report conflicting findings [Carney and Freedland 
2012]. A potential source of conflicting findings is the type of measurement used to assess 
depressive and anxiety symptoms. Previous research indicated that self-reported symptoms of 
anxiety and depression are closely related in MI patients [Denollet et al. 2006]. In the current 
study, standardized interview ratings of a psychological distress dimension that involves the co-
occurrence of anxiety and depression symptoms, predicted recurrent MI and all-cause mortality. 
However, in a previous report of this study a cognitive/affective depression dimension measured 
with the Beck Depression Inventory version 1 (BDI-I) was not related to a combined endpoint of 
recurrent MI and cardiac mortality [Martens et al. 2010b]. This finding is similar to another 
study in which both somatic and cognitive/affective depressive symptoms were associated with 
adverse outcome following MI when measured with a structured diagnostic interview [Hoen et 
al. 2010a] while in the same sample a cognitive/affective dimension measured with the BDI was 
not associated with cardiac prognosis [de Jonge et al. 2006]. These findings suggest that the type 
of instrument used to measure depressive and anxiety symptoms could influence the estimates of 




Another difference between previous studies focusing solely on depression is that we 
found support for three somatic dimensions which represented cardiorespiratory/autonomic 
symptoms, sleep problems, and symptoms of functional disability/fatigue, while most studies 
included only one somatic dimension. However, similar clusters of somatic health complaints 
have been found previously in MI patients [Denollet 1994]. Future studies should assess whether 
these factors truly represent distinct dimensions of distress, since the use of other instruments 
than the HARS and HDRS might produce different underlying factors, and whether the different 
associations with outcome following MI can be replicated. 
 Anxiety is potentially related to various pathophysiological processes in patients with 
MI, including increased risk of ventricular arrhythmias [Watkins et al. 2006], reduced heart rate 
variability (HRV) [Martens et al. 2008], inflammatory processes [Pitsavos et al. 2006], increased 
platelet activity [Cameron et al. 1990] and HPA axis dysregulation [Vreeburg et al. 2010]. 
Unhealthy behavior, such as non-adherence to treatment, physical inactivity, an unhealthy diet 
and smoking might also explain part of the association. Anxiety is related to an unhealthy 
lifestyle in individuals at risk of CHD [Bonnet et al. 2005], and with lower adherence to various 
risk reducing recommendations in patients following an acute cardiac event [Benninghoven et al. 
2006; Kuhl et al. 2009]. An avoidant coping strategy is a maladaptive way of downregulating 
anxiety that might lead to a decline in cardiac health behavior among anxious post-MI patients 
[Benninghoven et al. 2006]. More research is needed to identify the pathophysiological and 
behavioral pathways underlying the association of general and specific manifestations of anxiety 
and cardiac prognosis. This is especially relevant since a variety of these mechanisms failed to 
explain the increase in risk of future cardiovascular events associated with generalized anxiety 
disorder in a previous study of patients with stable CHD [Martens et al. 2010a].  
Future research is also needed to assess whether demographic and clinical variables 




found distinct associations between anxiety dimensions with variables included in the 
multivariate model in this study. Females were more likely to experience somatic symptoms of 
anxiety, while no association was found for psychological anxiety with gender. Further, cardiac 
history was positively related to somatic anxiety only. In addition, patients with more 
psychological anxiety symptoms tended to be younger (data not shown). Further research on this 
topic could give indications on factors related to the etiology of somatic and psychological 
distress. Also, future studies should evaluate whether there are differential associations between 
symptom dimensions of distress and mechanisms leading to adverse cardiac outcomes. Lower 
HRV has been shown to be associated with somatic but not with cognitive/affective depressive 
symptoms in patients with CHD [de Jonge et al. 2007]. In a study on persons with depression 
and/or anxiety, especially somatic symptoms of depression and anxiety were related to 
inflammatory markers [Duivis et al. 2013] although these associations might for a large part be 
the result of an unhealthy lifestyle associated with depression and anxiety [Duivis et al. 2013]. 
Overall these findings indicate that more research is warranted to assess whether specific 
relations between dimensions of distress and physiological, but also behavioral mechanisms, can 
be identified.  
Notably, both the somatic and psychological dimensions of anxiety were not related to 
LVEF as a marker of disease severity in the current study. In contrast, previous studies in 
patients with MI or ACS indicated that somatic depressive symptoms measured with the BDI-I 
were related to LVEF or Killip class [De Jonge et al. 2006; Martens et al. 2010b; Roest et al. 
2011]. Future studies could assess whether the association between depression and LVEF can be 
explained by specific somatic depressive symptoms. For example, a recent study showed that 
scores on the BDI-I may partly reflect symptoms of the medical condition in MI patients [Delisle 




Previous studies also showed that risk estimates of anxiety predicting cardiac outcomes 
were only slightly or not attenuated after adjustment for disease severity [Roest et al. 2010; 
Roest et al. 2012]. In order to reduce possible confounding in the period immediately after the 
MI, anxiety was measured at 2 months post-MI, and we adjusted for various cardiac risk factors. 
However it is impossible to completely rule out the possibility of residual confounding and 
underlying pathophysiology might still explain part of the relationship between anxiety and 
cardiac prognosis in the current study.  
Although the HARS is a widely used instrument to assess anxiety, there is a large overlap 
with depression features and one item specifically addresses depressed mood [Maier et al. 1988]. 
In addition, especially the somatic symptoms of the HARS could be indicative of higher levels of 
depression severity [Vaccarino et al. 2008]. Because of the high correlation between the HARS 
and the HDRS we could not assess whether the association of anxiety and its dimensions with 
cardiac prognosis is independent from depression which is an important limitation of this study. 
Nonetheless, the results of the current study suggest that anxiety and depression in MI patients 
might be better seen as two aspects of a general distress construct from which a psychological 
and one or more somatic dimensions can be deduced. However, this should be further 
investigated by studies using anxiety and depression measurements that are more distinctly 
different from each other. Another limitation is that, because of the relatively small sample size, 
we could not assess potential gender differences in the relationship between symptoms 
dimensions of anxiety and cardiac outcomes. In addition, females were less likely to have a 
HARS assessment and this may have led to a relatively low prevalence of patients with severe 
anxiety and depression. The prevalence of anxiety disorders and MDD was lower in the current 
study as compared to other studies in MI and stable CHD patients [Roest et al. 2012, Martens et 
al. 2010a]. Although, a study in patients with stable coronary artery disease showed that most of 




GAD [Frasure-Smith and Lespérance 2008], several other studies showed a dose-response 
relationship between depressive and anxiety symptom scores and adverse outcomes in different 
patient groups [Zuidersma et al. 2013; Rosenbloom et al. 2009]. This indicates that mild 
symptoms of distress are also related to cardiac prognosis. Finally, we had no information on the 
overall response rate of the study. However, we previously reported that the response rate in a 
subsample of patients was 73% [Martens et al. 2010b]. Despite the aforementioned study 
limitations, a broad spectrum of possible confounding factors was evaluated in this study. 
Furthermore, this study was a multi-centre study, making generalization of our results to the 
population of acute MI patients more justified. 
In summary, this study showed that anxiety was associated with adverse prognosis in MI 
patients with significant associations for somatic anxiety and total anxiety. There was a large 
overlap in anxiety and depressive symptoms and when combining anxiety and depression items, 
psychological distress and cardiopulmonary/autonomic symptoms predicted recurrent MI and 
mortality. Future research might better focus on dimensions of anxiety and depression 
simultaneously in MI patients. Also future studies should identify whether these symptom 
dimensions have different etiologies and whether mechanisms leading to adverse cardiac 
outcomes vary for dimensions of psychological and somatic distress. 
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Demographic variables     
Age, years mean (SD)   59 (11.4) 65 (13.3)   58 (10.8) <0.01 
Female gender   79 (18.9)   8 (16.0)   71 (19.3)   0.58 
Partner  345 (82.7) 39 (79.6) 306 (83.2)   0.54 
Educational level: high 229 (54.9) 22 (44.9) 207 (56.2)   0.13 
Clinical characteristics     
Cardiac history   65 (15.6)   20 (40.0)   45 (12.2) <0.01 
LVEF %, mean (SD)   50 (9.5)   45 (11.2)   50 (9.0) <0.01 
Multi-vessel disease 135 (37.8)   18 (45.0) 117 (36.9)   0.32 
Anterior MI location 155 (40.8)   15 (34.9) 140 (41.5)   0.40 
Comoborbidity   88 (21.2)   17 (34.0)   71 (19.4)   0.02 
Invasive treatment 258 (61.7)   24 (48.0) 234 (63.6)   0.03 
Cardiac rehabilitation 263 (67.1)   26 (54.2) 237 (68.9)   0.04 
Medication use     
Beta-blockers  361 (86.6)   43 (86.0) 318 (86.6)   0.90 
ACE-inhibitors  154 (37.0)   15 (30.0) 139 (38.0)   0.27 
Anti-coagulants  351 (84.2)   44 (88.0) 307 (83.7)   0.43 
Statins 382 (91.6)   40 (80.0) 342 (93.2) <0.01 
Aspirin  344 (82.5)   37 (74.0) 307 (83.7)   0.09 




SSRIs   50 (12.2)   11 (22.0)   39 (10.8)   0.02 
Smoking 163 (39.1)   20 (40.0) 143 (39.0)   0.89 
BMI, mean (SD)   27.0 (4.0)   26.7 (4.6)   27.0 (3.9)   0.62 
Hypertension   88 (22.1)     7 (14.3)   81 (23.1)   0.16  
Hypercholesterolemia   43 (10.7)     1 (2.1)   42 (11.9)   0.04  
Cardiac function     
Systolic  blood pressure, mean (SD) 141 (29) 138 (27.1) 141 (28.9)   0.38 
Diastolic blood pressure, mean (SD)   83 (17)   79 (17.9)   83 (16.5)   0.13 
Psychiatric morbidity     
HARS score ≥ 18 40 (9.6) 8 (16.0) 32 (8.7) 0.10 
Current anxiety disorder 16 (3.9) 5 (10.0) 11 (3.1) 0.02 
Current MDD 23 (5.6) 6 (12.0) 17 (4.7) 0.04 
Values are expressed as n (%) of patients unless otherwise indicated 
ACE= angiotensin-converting enzyme; BMI= Body mass Index; COPD= chronic obstructive 
pulmonary disease; HARS= Hamilton Anxiety Rating Scale; LVEF= left ventricular ejection 
fraction; MDD= major depressive disorder; MI= myocardial infarction; SSRIs= selective 






Table 2.  Pattern matrix of principal component analysis 
HARS items Somatic component Psychological component 
1. Anxious mood 0.11 -0.84 
2. Tension 0.13 -0.81 
3. Fears -0.12 -0.29 
4. Insomnia 0.47 -0.14 
5. Intellectual 0.28 -0.30 
6. Depressed mood 0.09 -0.77 
7. Somatic (muscular) 0.62 -0.04 
8. Somatic (sensory) 0.66 0.06 
9. Cardiovascular symptoms 0.58 0.04 
10. Respiratory symptoms 0.59 -0.08 
11. Gastrointestinal symptoms 0.68 0.10 
12. Genitourinary symptoms 0.17 -0.15 
13. Autonomic symptoms 0.77 -0.02 














Table 3. Association between somatic and psychological anxiety with recurrent MI and 
mortality 
Predictor variables HR 95% CI p 
Model 1a    
Somatic component 1.32 1.05-1.64   0.02 
Model 1b    
Psychological component 1.14 0.89-1.47   0.31 
Model 2a    
Somatic component 1.32 1.03-1.69   0.03 
Age 1.04 1.01-1.07 <0.01 
Female gender 0.67 0.31-1.47   0.32 
Cardiac history 2.36 1.26-4.41 <0.01 
LVEF % 0.96 0.94-0.99 <0.01 
Model 2b    
Psychological component 1.29 0.99-1.67   0.06 
Age 1.04 1.02-1.07 <0.01 
Female gender 0.75 0.35-1.62   0.47 
Cardiac history 2.72 1.49-4.98 <0.01 
LVEF % 0.96 0.94-0.99 <0.01 






Figure 1. HARS score ≥ 18 and association with recurrent MI and mortality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
